Clinical Characteristics of Toxicities of Immune Checkpoint Inhibitors and Their Impact on Efficacy in Solid Cancers: An Analysis of Real-World Data in Moroccan Patients

• DOI: 10.1200/go-24-00312
• Publication Date: 2025-02-27T20:59:11Z
• Authors: Badiaa Batlamous; Sihame Lkhoyaali; Loubna Omri; Magaly-Gwen-Farne...; Mohamed Khalis; Hanane Inrhaoun; Sarah Naciri; Ibrahim El Ghissassi; Hind Mrabti; Saber Boutayeb; Hassan Errihani
• Keywords: Atezolizumab

PURPOSE Patients receiving immune checkpoint inhibitors (ICIs) may induce immune-related adverse events (irAEs). This study aimed to evaluate the toxicity induced by ICIs and explore correlation between efficacy in a Moroccan population. METHODS We conducted prospective of patients with solid tumors who received pembrolizumab or atezolizumab at National Institute Oncology, Rabat from July 2018 December 2023. identified irAEs according ASCO 2021 guidelines graded them Common Terminology Criteria for Adverse Events Version 4.0. Efficacy respect progression-free survival (PFS) overall (OS) was determined. A Cox regression model used determine association survival. RESULTS Eighty-six were included. The primary tumor types lung (40.7%), skin (29.1%), GI cancer (14%). most commonly included (67.4%) (32.6%). as monotherapy (77.9%) combination (22.1%). total 58 presented any kind irAEs. common toxicities both groups GI, rates 25.3% 31.5%, respectively. showed significantly longer median PFS compared those without (9 v 3.6 months; hazard ratio [HR], 0.5 [95% CI, 0.32 0.99]; P = .04). OS than but not statistically significant (19 10.3 HR, 0.8 0.39 1.7]; .5). CONCLUSION Our results indicated that have potential tumors. These effects GI. development associated improved effectiveness ICI treatment across different malignancies.